The sequencing identifies overexpression of checkpoint molecules such as PD-L1 and CTLA-4 in relation to the specific percentage of RCC tumors that form a basis for immune checkpoint inhibitor therapy. The gene discussed is CD274; the disease is renal cell carcinoma.